International Society for Anti-infective Pharmacology (ISAP)

Slides:



Advertisements
Similar presentations
Is Vancomycin Obsolete for Treating Serious Staphylococcal Infections? Part I Edward L. Goodman, MD, FACP, FIDSA, FSHEA August 26, 2009.
Advertisements

Animal Model PK/PD: A Tool for Drug Development
Pharmacodynamics and the Dosing of Antibacterials
April 1st, 2006ISAP-ECCMID PK/PD Workshop - Nice, France 1 PK/PD modeling : Clinical Implications J.W. Mouton Dept Medical Microbiology, Canisius Wilhelmina.
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Chapter 10: Restricting antibiotic use and optimizing dosing.
Pharmacodynamics of Antibiotics
The (important) role of the pharmacist in the handling of COPD - H. Lode - Free University Berlin.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.
PK/PD - ICC - Manila, June 5th, The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul.
Use of in vitro models to study the emergence of resistance Professor Inga Odenholt Department of Infectious Diseases University hospital, Malmö Sweden.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Preclinical Models to Support Dosage Selection
Quinolone and Aminoglycoside Antibiotics Edgar Rios, Pharm.D., BCPS MHH Clinical Pharmacist UTHSCH Clinical Assistant Professor.
The Endpoint from a Resistance Point of View A Symposium to Honor the Career of William A. Craig, M.D. George Drusano, M.D. Co-Director Ordway Research.
Ten Years After: Where is ISAP?
Pharmacodynamics of Antifungals
The Rational Use of Antibiotics
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
PK/PD: TOWARDS DEFINITIVE CRITERIA PK/PD in clinical Practice: new level of PK/PD Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy,
JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.
Pharmacodynamics of Antimicrobials William A. Craig, M.D. University of Wisconsin-Madison.
Agents for the Treatment of MRSA: Pharmakokinetics &Pharmacodynamics
MACROLIDES: pharmacokinetics and pharmacodynamics
Antibiotic combinations vs. monotherapy in critical care
Relationship between resistance, antibiotic policies, and clinical guidelines in the community ? Government interventions on Antibiotic Policy in Belgium*
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
International Society for Anti-infective Pharmacology (ISAP)
Intracellular antibiotics and Listeria monocytogenes
In vitro pharmacodynamic models for the study of antibiotic activity against bacterial biofilms Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire.
The good and the bad uses of fluoroquinolones in Urology
Unité de Pharmacologie Cellulaire et Moléculaire
Allie punke pharmcokinetics Allie punke
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
Pharmacokinetics of Old and New Glycopeptides
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.
Azalides revisited: Why the single dose ? The pharmacologist's answer … Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of.
WP2: Development of a library of PK-PD indices and EDR targets
This poster will be made available for download after the meeting at :
The aminoglycoside antibiotics
Introduction Results Aim Methods References Conclusion
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Paul M. Tulkens Françoise Van Bambeke
Towards clinical Applications of PK-PD in specific situations
Unité de Pharmacologie Cellulaire et Moléculaire
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
PK/PD: from theory to applications in the real world...
Activity of Moxifloxacin against Staphylococcus aureus in Models of Persistent Infections (Intracellular Survival, Biofilms) Mailing address: P.M. Tulkens.
Simone M. Shurland, Ph.D., Division of Anti-Infective Products
Doripenem vs Meropenem: a summary of International and Belgian published data Françoise Van Bambeke, Unité de Pharmacologie cellulaire et moléculaire Louvain.
Antibiotics in 2005: Which one do we need to use and when ?
W.W. Hope, G.L. Drusano  Clinical Microbiology and Infection 
Intracellular antibiotics
Françoise Van Bambeke, Dr Sc. Pharm, Agr. Ens. Sup.
Thomas P. Lodise, PharmD, G.L. Drusano, MD  Critical Care Clinics 
Pharmacodynamic indices in targeting therapy of critical infections
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations  D. Andes, W.A. Craig  Clinical Microbiology.
Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection C. Seral, M. Barcia-Macay, F. Van.
M.R. Jacobs  Clinical Microbiology and Infection 
Are intracellular drug concentrations relevant for efficacy
Presentation transcript:

International Society for Anti-infective Pharmacology (ISAP) Pharmacodynamics of antibiotics: Correlation between kinetics and activity Paul M. Tulkens Cellular and Molecular Pharmacology Unit & Centre for Clinical Pharmacy Catholic University of Louvain, Brussels, Belgium International Society for Anti-infective Pharmacology (ISAP) www.facm.ucl.ac.be www.isap.org PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Pharmacodynamics of antibiotics: Correlation between kinetics and activity Rising resistance and correlation with antibiotic use … Did we use antibiotics in a rational way ? … What is pharmacodynamics and how can it help you ? … Can we prevent (or slow down the emergence of) resistance ? … Can we also reduce health care costs ? … www.facm.ucl.ac.be www.isap.org PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Resistance is the problem … macrolides tetracyclines 40 penicillin* intermediate 35 penicillin* full resistant 30 1/3 patients 25 percentage 20 15 1/5 patients 10 5 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 20 * all -lactams (= penicillins, cephalosporins, …) year Belgian Reference Laboratory for pneumococci, Leuven, 2000 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Overuse is also the problem … Risk of resistance to -lactams among invasive isolates of Streptoccus pneumoniae regressed against outpatient sales of beta-lactam antibiotics in 11 European countries resistance data are from 1998 to 1999; antibiotic sales data 1997. DDD = defined daily doses Bronzwaer SL, Cars O, et al. Emerg Infect Dis 2002 Mar;8(3):278-82 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

be globally efficacious How can you be "better" ? be globally efficacious pharmacodynamics (PK/PD) avoid selection of resistance "mutant prevention concentration" PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

What is Pharmacokinetics / Pharmacodynamics (PK/PD) ? dose and schedule Pharmacokinetics: what the body does to the drug absorption, distribution, serum and tissue levels elimination, … Pharmacodynamics (of AB): what the drug does to the bacteria static vs. bactericidal effect, rate of kill, eradication, prevention of resistance…. Cmax t1/2 clearance Emax time to Emax prevention of relapses maintenance of susceptibility PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

The problem as seen from a question of the FDA... And what about those ones ? Same dose ?? Breakpoints tend to set up quantic limits in what is fundamentally a continuous distribution ... PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

What are "Pharmacodynamic indices" ? all drugs have pharmacokinetic properties that describe the way the body handles them antibiotics are no exception … you need to consider the Cmax and the clearance (that will result in a given half-life) to describe the drug exposure a drug needs to bind to its target to act … antibiotics are again no exception, but the target is the bacteria … the antibiotics can be studied in vitro to look at the extent of their action at increasing concentrations (like the binding of a ligand to its receptor in conventional pharmacology). This is drug pharmacodynamics… PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Pharmacokinetics  Pharmacodynamics... conc . vs effect 10 -3 Conc . (log) Effect Pharmacokinetics conc . vs time Conc Time 25 0.0 0.4 PK/PD effect vs time Time Effect 1 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Example of a pharmacodynamic relationship Emin Emax MIC Barcia-Macay et al. Antimicrob. Agents Chemother. 2006; 50(3):841-51 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

And what if we put pharmacokinetics ? Cmin-Cmax Emin Emax MIC Barcia-Macay et al. Antimicrob. Agents Chemother. 2006; 50(3):841-51 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

And what if we put pharmacokinetics ? low concentration dependency Cmin-Cmax high concentration dependency Barcia-Macay et al. Antimicrob. Agents Chemother. 2006; 50(3):841-51 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

From Pharmacokinetics to Pharmacodynamics of AB … Peak / MIC AUC / MIC Time > MIC PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

A simple dynamic model … Pump Fresh Medium Waste Inflow = Clearance Drug Conc. Peak T1/2 = 0.693 * V/Cl AUC Sampling of Drug, Bacteria V Time Adapted from M.N. Dudley, ISAP / FDA Workshop, March 1st, 1999 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Pharmacodynamics: the basic question … Which antibiotics are time- AUC peak- dependent in clinically meaningful conditions ? PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Main PK/PD properties of antibiotics Available antibiotics can be divided in 3 groups : time - dependent (T > MIC) AUC / MIC - dependent both AUC / MIC and peak / MIC -dependent PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Antibiotics Group # 1 (after W.A. Craig, 2000; revised 2002 and 2003) 1. Antibiotics with time-dependent effects and no or little persistent effects AB -lactams PK/PD parameter Time above MIC Goal Maximalize the exposure time time above the MIC PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

How long should you stay above the MIC ? 40 % Moderate infections cefotaxime neutropenic mice K. pneumoniae lung infection 100 % Serious infections PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Do all -lactams have similar PK/PD properties ?... different pathogens same shape of dose response diff. In T > MIC for a static effect (penicill. > carbap.) diff Emax (penicill. < carbap.) Andes & Craig Int. J. Antimicrob. Agents 2002, 19: 261-268 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Dosing amoxycilline for respiratory tract infections in Belgium Sensitivity of S. pneumoniae to amoxycillin Dose and schedule for T > CMI = 50 % 0.01 0.10 1.00 25 50 75 100 1000 mg 3 x / j 500 mg 3 x / j 500 mg 2 x / j cumulative % of strains S I R CMI MIC data: J. Verhaegen et al., 2001 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Antibiotics Group # 2 (after W.A. Craig, 2000; revised 2002 and 2003) Antibiotics with time-dependent effects, no or little influence of concentration, but marked, persistent effects AB glycopeptides tetracyclines macrolides linezolid streptogramins PK/PD parameter AUC / MIC Goal optimize the amount of antibiotic PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Antibiotics Group # 3 (after W.A. Craig, 2000; revised 2002 and 2003) Antibiotics with concentration-dependent bactericidal activity and prolonged persistent effects (post-antibiotic effects) AB aminoglycosides fluoroquinolones daptomycin ketolides PK/PD parameter Peak and AUC / CMI Goal optimize the peak and the amount of antibiotic PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Aminoglycosides: get a peak ! Appropriate mode of administration IV route 2. Calculation of the necessary peak value minimal peak: = MIC / 8 3. Calculation of the adequate dosis peak = dosis / Vd dosis = peak x Vd dosis = MIC x 8 x Vd PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Aminoglycosides: why a peak ? Aminoglycosides are concentration-dependent drugs in the clinically meaningful concentration range ... PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Aminoglycosides: why a peak ? Clinical efficacy is linked to peak/MIC ratio PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Fluoroquinolones: get a peak and an AUC ! increase the amount administered, in order to optimize AUC/MIC and peak/MIC should be > 125 * should be > 10 Get both a peak and a AUC !! Concentration MIC Time (h) PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Why an AUC / MIC > 125 for fluoroquinolones ... AUC / MIC is one parameter … Forrest et al., AAC, 1993 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

What do you mean by PEAK /MIC > 10 and AUC / MIC > 100 low ratio MIC high ratio MIC AUC24h = dose / clearance PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

AUC/MIC24h =125 : a magical number?? 125 was the limit below which failure rates became unacceptable because of either a large MIC or a too low dosage (AUC is proportional to the dosage) PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Is 125 good for all ?? The saga of S. pneumoniae ... non-neutropenic 24 Hr AUC/MIC Mortality (%) 1 2.5 5 10 25 50 100 20 40 60 80 non-neutropenic Emax at 30 ... 3 30 300 10 100 1000 20 40 60 80 24 hr AUC/MIC Percent mortality neutropenic Emax at 125 ... PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

How to optimize the AUC / MIC ratio ? AUC = dosis / Cl Adjust the daily dosis ~ target AUC Adapt the number of administrations ~ pharmacokinetics of the drug PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Mutant Prevention Concentration … 1 MIC 99 = 0.8 10 -2 "Classic" bactericidal effect 10 -4 poorly sensitive organisms… Surviving bacteria 10 -6 10 -8 Elimination of resistant organisms -10 MPC 10 = 9 10 0.01 0.10 1.00 10.00 concentration Dong et al; AAC 43:1756-1758 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Mutant Prevention Concentration … Concentration which will inhibit the majority of the organisms 1 MIC 99 = 0.8 10 -2 10 -4 Surviving bacteria 10 -6 Concentration needed to prevent the selection of resistant organisms 10 -8 10 -10 MPC 10 = 9 0.01 0.10 1.00 10.00 concentration Dong et al; AAC 43:1756-1758 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

"Window" where selection of mutants/resistants may take place … Mutation selection window MPC concentration MSW MIC Time after administration concept from Drlica & Zhao, Rev. Med. Microbiol. 2004, 15:73-80 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Molecule MIC MPC Cmax levoflox. 1 8 6 4 moxiflox. 0.25 1 Which are the MPC values compared to - MIC for S. pneumoniae - Cmax for a standard dose ? Cmax 6 4 (500 mg) (400 mg) Molecule MIC MPC levoflox. 1 8 moxiflox. 0.25 1 Adapted from D. Croisier, 2005, Bondeau et al., 2001, and Hansen et al, 2003 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

So, let us accept values with some degree of precaution If you wish to prevent resistance peak / MIC > 10 (which covers the MPC) If you believe your patient is not a healthy mouse … AUC24h / MIC > 100 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

A proposal for PK/PD based-breakpoints for fluoroquinolones... Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect. 2005 Apr;11(4):256-80. PMID: 15760423 PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

PK/PD in action … Levofloxacin 500 mg 1X / jr AUC [(mg/l)xh] 47 peak [mg/l] 5 MICmax < 0.5 PK/PD breakpoint % of sensitive strains 20 40 60 80 100 moxi MIC data: J. Verhaegen et al., 2003 levo Moxifloxacin 400 mg 1X /jr AUC [(mg/l)xh] 48 peak [mg/l] 4.5 MICmax < 0.5 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 MIC PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

no yes A clinical algorithm ... Pathology and epidemiology Knowledge or ou “educated” suspicion of the causative agent Pathology and epidemiology Local MIC data Is the organism probably highly susceptible ? Use common dosage but with attention to PK/PD yes Obtain an MIC no Adjust the dosage on a full PK/PD basis S / I / R is insufficient !! PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

A clinical algorithm (follow.) ... Success ? re-evaluate the dosage the therapeutic scheme the antibiotic class based on PK/PD properties no Consider step-down therapy if acceptable on a microbiological point of view yes Use these pieces of information to establish recommendations based on local epidemiology and on the knowledge of the PK/PD properties and of the risk for resistance PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

And what about health care costs ? Pharmacoeconomics Economic cost minimization cost benefit cost effectiveness cost utility Humanistic quality of life patient's preference patient's satisfaction L. Sanchez, In Pharmacotherapy, DiPiro et al. eds, p.2, 1999 Pharmacoeconomics of antibiotics is still largely underdeveloped outside the USA (but US-based models cannot easily be applied); However, comparisons identifying differences in amount of money needed to reach a given (better ? ) clinical outcome; expenses related to the same (or better) quality of life and patient's satisfaction; may already suggest interesting avenues for further fine-tuning therapeutic guidelines PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Rational bases for the choice of an antibiotic Know your LOCAL epidemiology obtain MIC distributions from your microbiologists… know the PK profile of the drugs you consider to purchase aim at obtaining > 90 % efficacy against the organisms of interest (AUC, peak, time above MIC) with a standard dosage, … include a safety margin (MPC …) Compare products on that basis first … Remember that no antibiotic (if possible) is the best… but that treatment failures (when treatment is needed) cost a lot … PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06

Please, act … W.A. Craig, MD M.N. Dudley, Pharm. G.L. Drusano, MD J.J. Schentag, Pharm. A. McGowan, MD X. Zao, PhD V. Firsov, MD S. Zinner, MD A. Dalhoff, PhD ... www.isap.org www.antiinfectieux.org F. Van Bambeke, Pharm. A. Spinewine, Pharm. S. Carryn, Pharm. H. Chanteux, Pharm. H. Servais, Pharm. ... PD of antibiotics: correlation between kinetics and activity Tunis - 18-04-06